Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Jun;17(3):385-92.
doi: 10.1016/j.cbpa.2013.03.029. Epub 2013 Apr 25.

Targeting T Cells to Tumor Cells Using Bispecific Antibodies

Affiliations
Review

Targeting T Cells to Tumor Cells Using Bispecific Antibodies

Stanley R Frankel et al. Curr Opin Chem Biol. .

Abstract

The immune system, and in particular T cells, can be harnessed to treat cancer. Several bispecific T cell engaging antibodies of the BiTE® format are in early or late-stage clinical development. These small recombinant antibody constructs effectively trigger killing of cancer cells by temporarily attached, polyclonal T cells. Blinatumomab, a CD19/CD3-bispecific BiTE® antibody, has demonstrated high clinical activity in B cell leukemia and lymphoma patients. Three additional BiTE antibodies directed against surface target antigen expressed on solid tumors are being evaluated in phase I clinical trials. Alternative approaches to direct polyclonal T cells to kill cancer cells are under intense investigation.

Similar articles

See all similar articles

Cited by 54 articles

See all "Cited by" articles

Substances

LinkOut - more resources

Feedback